TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Adult Subjects With Uncontrolled Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with uncontrolled T2DM who have received diet and exercise therapy for at least 3 months prior to screening, aged ≥ 18 - ≤ 75 years~2. Females must be post-menopausal, unable to conceive, or test negative for pregnancy via blood test and use barrier contraception~3. BMI ranging from ≥ 20 to ≤ 40 kg/m2~4. Fasting plasma glucose values of up to 240 mg/dL at screening, after wash-out (visit 2) and after placebo run-in (visit 3)~5. (i) naïve or (ii) currently using and discontinued metformin or (iii) no prior exposure to anti-diabetic agents other than metformin ≥ 6 months prior to screening~Exclusion Criteria:~1. History of Type 1 diabetes~2. History of more than 1 episode of severe hypoglycemia within 6 months prior to screening, or a current diagnosis of hypoglycemia unawareness.~3. Hospitalizations or Emergency room visits that would impact patient safety or data interpretation:~   1. Due to poor glucose control in the 6 months prior to screening or~  2. Any bariatric surgical procedures for weight loss.~4. Significant change of body weight (\>10%) in the 3 months before screening~5. Proliferative retinopathy or maculopathy within the 6 months before screening or requiring acute treatment, or severe neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 100 mg q.d. (Type: ACTIVE_COMPARATOR): None
- 100 mg b.i.d. (Type: ACTIVE_COMPARATOR): None
- 200 mg q.d. (Type: ACTIVE_COMPARATOR): None
- 200 mg b.i.d. (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gender: Male or female~* Age: \>12 yrs of age~* Presentation: 1-to-2 ulcerative lesions, each \< 30 mm in largest diameter and with a total lesion area \<900 mm2.~* Parasitology: Parasitological confirmation of the lesion will be made by visualization or culture of Leishmania from the biopsy or aspirate of the lesion.~Exclusion Criteria:~* Previous treatment for leishmaniasis with Sb, pentamidine, amphotericin B, miltefosine, imidazoles, allopurinol in the last 3 months.~* Other diseases that would be likely in the PI's opinion to interact, either positively or negatively, with treatment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 - Paromomycin cream (Type: EXPERIMENTAL): 40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
- Group 2. Local Injectable Pentamidine (Type: ACTIVE_COMPARATOR): 20 subjects will be included to receive IL pentamidine \[Pentacarinat® Sanofi-Aventis: 30 mg/ml\] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area.
- Group 3. Vehicle control (Type: PLACEBO_COMPARATOR): 10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities:~  * Follicular lymphoma grade 1 and 2~ * Immunocytoma and lymphoplasmocytic lymphoma~ * Marginal zone lymphoma, nodal and generalised~ * Mantle cell lymphoma~ * lymphocytic lymphoma (CLL without leucaemic characteristics)~ * non-specified/classified lymphomas of low malignancy~* No prior therapy with cytotoxics,interferon or monoclonal antibodies~* Need for therapy, except mantle cell lymphomas~* Stadium III or IV~* Written informed consent~* Performance status WHO 0-2~* Histology not older than 6 months~Exclusion Criteria:~* Patients not establishing all above mentioned prerequisites~* Option of a primary, potential curative radiation therapy~* Pretreatment except a unique local delimited radiation (radiation fiel not expanding two adjacent lymph node regions~* Comorbidities excluding a study conform therapy:~  * heart attack during the last 6 months~ * severe, medicinal not adjustable hypertonia~ * severe functional defects of the heart (NYHA III or IV)~ * lung (WHO grade III or IV), liver or kidney (creatinine \> 2 mg/dl, GOT + GPT or bilirubin 3 x ULN, except caused by lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine + Rituximab (Type: EXPERIMENTAL): Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
- CHOP + Rituximab (Type: ACTIVE_COMPARATOR): Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Males and females, 18 to 89 years old, with type 2 diabetes with inadequate glycemic control HbA1c between 7-10.5% and uncontrolled hypertension Systolic Blood Pressure (SBP) 140-165 and Diastolic Blood Pressure (DBP) 85-105~* Subjects must have a mean 24 hr blood pressure ≥ 130/80 determined by Ambulatory Blood Pressure Monitoring (ABPM) within 1 week prior to Day 1 visit~* Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks \[12 wks for Thiazolidinedione (TZD)\] or a stable daily dose of insulin, as a monotherapy or in combination with another OAD, for 8 weeks, and a stable dose of ACEI or ARB and 1 additional antihypertensive medication for at least 4 weeks~* C-peptide ≥ 0.8 ng/mL~* Body Mass Index ≤ 45.0 kg/m2~* Serum creatinine \< 1.50 mg/dL for men or \< 1.40 mg/dL for women~Exclusion Criteria:~* Aspartate aminotransferase (AST) and /or Alanine aminotransferase (ALT) \> 3.0\*upper limit of normal (ULN)~* Serum total bilirubin ≥ 1.5\*ULN~* Creatinine kinase \> 3\*ULN~* Symptoms of severely uncontrolled diabetes~* History of malignant or accelerated hypertension~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 10 mg (Type: EXPERIMENTAL): Dapagliflozin 10 mg tablets
- Placebo matching Dapagliflozin (Type: PLACEBO_COMPARATOR): Placebo tablets matching dapagliflozin tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with primary histologically proven stage pTa-pT1 transitional-cell carcinoma of the bladder~Exclusion Criteria:~* Previous treatments with bacillus Calmette-Guerin, mitomycin-C, or with any other intravesical cytostatic agent~* Concomitant urothelial tumours of the upper urinary tract~* Previous or concomitant muscle-invasive (ie, stage T2 or higher) transitional-cell carcinoma of the bladder~* Bladder capacity less than 200 ml~* Untreated urinary-tract infection~* Disease of upper urinary tract~* Previous radiotherapy to the pelvis~* Other concurrent chemotherapy~* Treatment with radiotherapy-response or biological-response modifiers~* Other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma)~* Pregnancy or nursing~* And psychological, familial or sociological factors that would preclude study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- transurethral resection alone (Type: NO_INTERVENTION): Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
- intravesical mitomycin-C (Type: ACTIVE_COMPARATOR): Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
- electromotive mitomycin-C (Type: EXPERIMENTAL): Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Tobacco Marijuana

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals must be 18 years or older~2. Individuals must meet criteria for the current Diagnostic and Statistical Manual -IV diagnosis of cannabis abuse or dependence, report use of cannabis on at least 45 of the previous 90 days, and report regular use of tobacco cigarettes or report that their primary administration of cannabis is via blunts or spliffs~3. Individual must indicate that they have at least some interest in quitting tobacco in the next 6 months (rating of 2 or more on a 5-point interest scale)~Exclusion Criteria:~1. Current dependence on alcohol or any drug other than tobacco and cannabis~2. Use of non-tobacco nicotine~3. Current participation in structured treatment for substance abuse~4. Severe psychological distress (e.g., active suicidal plans, psychosis, debilitating panic disorder)~5. Report of a condition that requires seeing a physician before using NRT (e.g., pregnancy or recent heart attack); note: if a participant's physician approves taking NRT, we will consider enrolling them~6. Legal status that would interfere with participation~7. Living with someone currently enrolled in the project~8. Not being fluent in English~9. Not living within 45 miles of the research site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CUD Treatment Only (Type: ACTIVE_COMPARATOR): 12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
- CUD and Tobacco Treatment (Type: EXPERIMENTAL): 12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of trichiasis:~* no previous report of trichiasis surgery in at least one eye with trichiasis:~* Agreement by at least one other family member accompanying the patient that, if the patient is randomized to the family-treatment arm, s/he also would be willing to receive antibiotic treatment~* Age 18 or older~Exclusion Criteria:~* other household members concurrently participating in the trial~* Self-reported pregnancy~* Documented allergy to tetracycline~* Plans to move out of the region within 1 year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): topical tetracycline
- Intervention 1 (Type: ACTIVE_COMPARATOR): oral azithromycin, single 1g dose to subject
- Intervention 2 (Type: ACTIVE_COMPARATOR): single oral azithromycin dose to subject and immediate family members

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus prior to informed consent~2. Male and female patients on diet and exercise regimen who are drug-naïve (defined as absence of any oral antidiabetic therapy, glucagon like peptide-1 analog or insulin for 12 weeks prior to randomization) or pre-treated with metformin (=1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.~3. Glycosylated hemoglobin (HbA1c) = 7.0% and = 10.5% (= 53.0 mmol/mol and = 91.3 mmol/mol) at Visit 1 (screening)~Exclusion criteria:~1. Uncontrolled hyperglycemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day).~2. Any other antidiabetic drug within 12 weeks prior to randomization (except metformin background therapy as defined via inclusion criterion 2)~3. Acute coronary syndrome (non-ST elevation myocardial infarction, ST elevation myocardial infarction and unstable angina pectoris), stroke or (transient ischemic attack) TIA within 3 months prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773/linagliptin FDC (high dose) (Type: EXPERIMENTAL): Patients receive BI 10773/linagliptin FDC (high dose) once daily
- BI 10773/linagliptin FDC (low dose) (Type: EXPERIMENTAL): Patients receive BI 10773/linagliptin FDC (low dose) once daily
- BI 10773 (high dose) (Type: ACTIVE_COMPARATOR): Patients receive BI 10773 (high dose) once daily
- BI 10773 (low dose) (Type: ACTIVE_COMPARATOR): Patients receive BI 10773 (low dose) once daily
- Linagliptin (Type: ACTIVE_COMPARATOR): Patients receive linagliptin once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Study of Talk Parenting Skills

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~1. Parent learned about the study through a participating agency~2. Child 3-5 years old who lives with the parent at least half time~3. Parent puts the child to bed at least 2 nights per week~4. Able to read and understand English~5. Has access to the internet at home.~Exclusion:~1. Families of target-age children with a developmental disability severe enough that the child cannot speak or follow simple directions will be excluded; their needs are beyond the scope of Talk Parenting.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- The Talk Parenting Skill for Alexa - Parent (Type: EXPERIMENTAL): 49 parents will be assessed at enrollment, then provided an Amazon Echo Dot and exposed to the prototype Bedtime Routine module of the Talk Parenting program for 4 weeks, and then re-assessed at 4 weeks (at treatment completion)
- The Talk Parenting Skill for Alexa - Child (Type: EXPERIMENTAL): Although 49 children were considered enrolled participants that actively participate in the intervention, we obtained no assessment data from the children themselves.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ultrasound on Orthodontic Tooth Movement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects who meet all of the following criteria will qualify for entry into the study:~1. Scheduled to receive orthodontic treatment or in early stage of orthodontic treatment~2. Minimum of 3 mm of extraction space (on both sides of a dental arch) to be closed either by distal movement of all 6 anterior teeth from canine to canine or by distal movement of the canines.~3. Available for follow-up visits.~4. Willing and able to sign written informed consent.~5. Healthy.~6. Has permanent dentition and between the ages of 12 and 40.~7. Good oral hygiene and compliance~Exclusion Criteria:~Subjects who meet any of the following criteria will be excluded from the study:~1. Any compromised medical or dental condition that prevents the subject from participating in the trial or using the medical device.~2. Any implanted assistive devices.~3. Currently involved in any other study.~4. Lives significantly outside the clinical trial site.~5. Use of bisphosphonates.~6. Pregnant females .

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): 20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
- Control Arm (Type: SHAM_COMPARATOR): The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Standing Balance as the Fifth Vital Sign in Clinical Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Columbus Metropolitan Area by the following counties: Franklin, Madison, Union, Delaware, Locking, Fairfield, Pickaway.~* Physician, advanced practice registered nurse, or physician assistant, who diagnoses and treats patients in ambulatory outpatient settings~* self-report that falls are a concern for a significant fraction of the participant's patients, where the participants defines significant as they see fit.~* Participants must commit to using the test device as the primary weight scale in the clinic for the duration of the study to be selected.~Exclusion Criteria:~* No gender, ethnic, or racial groups will be excluded from this study, though it is expected that the majority of the sample will be Caucasian American, given that the professions of physicians, nurse practitioners, and physician assistants are predominantly Caucasian American.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group AB (Type: None): A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
- Group BA (Type: None): A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete